Experienced in Peripheral T-Cell Lymphoma

Wolfgang Herr

Franz Josef Strauss Allee 11, 
Regensburg, BY, DE 
Experienced in Peripheral T-Cell Lymphoma
Franz Josef Strauss Allee 11, 
Regensburg, BY, DE 
OverviewLocationsClinical Research

Overview

Wolfgang Herr practices in Regensburg, Germany. Mr. Herr is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Graft Versus Host Disease (GvHD), Cytomegalovirus Infection, Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 185 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Peripheral T-Cell Lymphoma.

Gender
Male

Locations

Franz Josef Strauss Allee 11, Regensburg, BY 93053, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 2

185 Total Publications

First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.
Journal: Cancers
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Herr's expertise for a condition
ConditionClose
View All 47 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile